This CME/CNE activity will highlight updates in secondary prevention of ischemic stroke and transient ischemic attack. The expert faculty, Dr. Stephan Mayer, will first delve into the pathophysiology and disease burden of early recurrent ischemic neurovascular events. Next, Dr. Mayer will review the importance of antiplatelet therapy with both ASA and P2Y12 inhibitors in acute and early secondary prevention. Following, the faculty will analyze the importance of risk stratification and net clinical benefit in managing early secondary prevention of recurrent ischemic neurovascular events. Finally, Dr. Mayer will examine optimal approaches of transition of ongoing care of their stroke patients to other healthcare professionals who provide more chronic and ongoing care.
Neurologists, and other clinicians, including nurses, NPs, and PAs who manage patients with stroke
- Understand the platelet-mediated pathophysiology and disease burden of early recurrent ischemic neurovascular events.
- Recognize the importance of antiplatelet therapy with both ASA and P2Y12 inhibitors in acute and early secondary prevention of recurrent ischemic neurovascular events.
- Review the importance of risk stratification and net clinical benefit in managing early secondary prevention of recurrent ischemic neurovascular events.
- Analyze optimal approaches of transition of ongoing care of their stroke patients to other healthcare professionals who provide more chronic and ongoing care.
- The Pathophysiology and Disease Burden of Early Recurrent Ischemic Neurovascular Events
- The Importance of Risk Stratification and Net Clinical Benefit in Managing Early Secondary Prevention of Recurrent Ischemic Neurovascular Events
- Optimal Approaches of Transition of Ongoing Care of their Stroke Patients to other Healthcare Professionals who Provide more Chronic and Ongoing Care
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Stephan A. Mayer, MD||Consultant/Advisor: AstraZeneca Pharmaceuticals|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 pharmacotherapeutic contact hour (Provider number P0491).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].